15 These advances are essential because with alcohol indelibly integrated into our culture, it is not likely that alcoholic liver disease will be going anywhere anytime soon. If I am wrong, then the next round is on me! “
“Background and Aim:  Recently, various non-invasive blood markers and indices have been studied to overcome the limitations of liver biopsy, such as its invasiveness and sampling errors. However, the majority of these studies have focused on patients with chronic hepatitis C. Accordingly, this study was performed to evaluate the significances of various non-invasive serum markers in terms of predicting the presence of liver cirrhosis in chronic hepatitis

B. Methods:  We included 125 chronic hepatitis B patients who had undergone liver biopsy. Fibrosis selleck screening library stage was assessed using the METAVIR scoring system (F0–F4), which defines liver cirrhosis as F4. In addition, we measured various blood markers at times of liver biopsy. Results:  Thirty four of the 125 patients (27.2%) were rated as F4 by liver biopsy. Age, platelet, white blood cells, aspartate aminotransferase (AST), alanine aminotransferase, haptoglobin, apolipoprotein-A1 (Apo-A1), collagen-IV, hyaluronic acid, α2-macroglobulin, matrix metalloproteinase-2,

and YKL-40 were significantly different between patients with chronic hepatitis and those with liver cirrhosis. However, multivariate analysis showed that only platelet, AST, haptoglobin, and Apo-A1 independently predicted the presence of liver cirrhosis. NVP-LDE225 Having identified these four factors, we devised a system, which we refer to as platelet count, AST, haptoglobin, and Apo-A1 (PAHA). The area under the receiver-operating characteristics (AUROC) of PAHA indices for the presence of liver cirrhosis was 0.924 (95% confidence interval, 0.877–0.971), which was

significantly greater than the AUROC of other indices of fibrosis. Conclusion:  The devised PAHA system was found to be useful for predicting the presence of liver cirrhosis in patients with chronic hepatitis B. “
“Background and Aim:  Liver fibrosis is closely associated with the progression of various chronic Palbociclib liver diseases. Fucoidan exhibits different biological properties such as anti-inflammatory, anti-oxidant and anti-fibrotic activities. The aim of this study was to determine whether oral fucoidan administration inhibits N-nitrosodiethylamine (DEN)-induced liver fibrosis. Methods:  Liver fibrosis was induced in rats by injecting DEN (50 mg/kg). Rats were given 2% of crude fucoidan solution or 2% of high-molecular-weight (HMW) fucoidan solution. They were divided into a crude fucoidan group, an HMW fucoidan group, a DEN alone group, a DEN + crude fucoidan group, a DEN + HMW fucoidan group and a control group.